Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study - Bousser, Marie-Germaine; Amarenco, P.; Chamorro, A.; Fisher, M.; Ford, I.; Fox, K.; Hennerici, Michael G.; Mattle, H. P.; Rothwell, P. M. (Cerebrovascular diseases, 2009)
Gesehen am 20.04.2022